Search

Displaying results 3581 - 3590 of 6951 in total
  1. Drug

    Cusatuzumab

    go.drugbank.com/drugs/DB15100
    Investigational

    syndrome (MDS) in patients unsuitable for chemotherapy. … [A241045] It is currently being investigated in the Phase 2 CULMINATE trial, in combination with [azacitidine], for the treatment of newly-diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic

  2. Drug

    Chloramphenicol

    go.drugbank.com/drugs/DB00446
    ApprovedInvestigationalVet approvedWithdrawn

    An antibiotic first isolated from cultures of Streptomyces venezuelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with ...

    Categories: Antibiotics for Topical Use, Antibacterials for Systemic Use
  3. Drug

    Trolamine

    go.drugbank.com/drugs/DB13747
    ApprovedInvestigational

    Trolamine, which is also referred to as triethanolamine (TEA), is a tertiary amine and a triol. It is a bifunctional compound that exhibits both properties of alcohols and amines. Trolamine contains small amounts of diethanolamine and et...

    Categories: Preparations for Treatment of Wounds and Ulcers
  4. Drug

    Dibekacin

    go.drugbank.com/drugs/DB13270
    Approved

    Dibekacin is an aminoglycoside antibiotic marketed in Japan .

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    ALTU-135

    go.drugbank.com/drugs/DB05330
    Investigational

    ALTU-135, the Company's orally administered enzyme replacement therapy for patients with pancreatic insufficiency, is manufactured by blending three drug substance enzymes: lipase, protease and amylase

  6. Drug

    Gataparsen

    go.drugbank.com/drugs/DB05141
    Investigational

    LY2181308 is investigated in clinical trials for treating solid tumors. LY2181308 is a solid. LY2181308 is directed against a molecular target called survivin. … LY2181308 is known to target baculoviral IAP repeat-containing protein 5.

  7. Target

    T-cell surface glycoprotein CD3 delta chain

    go.drugbank.com/bio_entities/BE0003456
    TargetHumans

    When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD247/CD3Z.

    Synonyms: T-cell receptor T3 delta chain
  8. Target

    T-cell surface glycoprotein CD3 gamma chain

    go.drugbank.com/bio_entities/BE0003457
    TargetHumans

    Indeed, constitutive TCR cycling is dependent on the di-leucine-based (diL) receptor-sorting motif present in CD3G … When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD247/CD3Z.

    Synonyms: T-cell receptor T3 gamma chain
  9. Target

    P2Y purinoceptor 4

    go.drugbank.com/bio_entities/BE0009822
    TargetHumans

    Receptor for UTP and UDP coupled to G proteins that activate a phosphatidylinositol-calcium second messenger system. Not activated by ATP or ADP

    Synonyms: Uridine nucleotide receptorFunction: G protein-coupled purinergic nucleotide receptor activity
  10. Drug

    Lucinactant

    go.drugbank.com/drugs/DB04897
    Approved

    Lucinactant is a new synthetic peptide-containing surfactant for intratracheal use.